Addressing Patient Hesitancy in Parkinson Treatment With Education: Mazen Elkurd, DO
The director of the Movement Disorders Center at Baylor University Medical Center in Dallas, a part of Baylor Scott & White Health, discussed patient reluctance towards new treatments for Parkinson disease and the role of education in defining treatment expectations for patients. [WATCH TIME: 4 minutes]
WATCH TIME: 4 minutes
"There is a need for more patient education because we do not do a good enough job of explaining what Parkinson disease is and its causes to patients. Also, patients often receive minimal guidance—such as 'Take this pill, 3 times a day'—without understanding the treatment's intentions or potential effects."
Parkinson disease (PD), a progressive neurodegenerative disorder, is characterized by motor and nonmotor symptoms. In research and clinical practice, the best way to manage motor and nonmotor symptoms of the disease is through a multidisciplinary and comprehensive approach. Among the key aspects of this approach, called the chronic care model, are patient-centered care, patient engagement and empowerment, and health literacy.1 Following this model will help with reducing reluctancy in patients trying new treatments and will allow patients to have a better understanding of their disease and managing it.
He also talked about the ways that patient education can be significantly enhanced to encompass a comprehensive understanding of the causes of PD and the intentions of its treatments. Elkurd, director of the Movement Disorders Center at Baylor University Medical Center in Dallas, a part of Baylor Scott & White Health, discussed how wearable technologies, like the Apple Watch and specialized devices, revolutionize the approach to PD care through continuous patient monitoring and treatment adjustments.
REFERENCES
1. De Pandis MF, Torti M, Rotondo R, et al. Therapeutic education for empowerment and engagement in patients with Parkinson's disease: A non-pharmacological, interventional, multicentric, randomized controlled trial. Front Neurol. 2023;14:1167685. Published 2023 Apr 18. doi:10.3389/fneur.2023.1167685
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Related Articles
- Pathophysiology of Myasthenia Gravis
September 18th 2025